News

Archive

Icosabutate latest phase 2b interim data show significant decreases in NASH and fibrosis biomarkers independent of fibrosis stage and disease severity Cambridge Epigenetix raises $88 million Series D financing to advance best-in-class DNA sequencing technology platform Novadip Biosciences announces EUR 19 million Series B financing backed by international investors VUV Analytics, Inc. Introduces the LUMA™ Multi-Channel Vacuum Ultraviolet Absorbance Detector BrightVolt raises $16 million in Series B funding led by New Science Ventures and Caterpillar Venture Capital Inc. Ventyx Biosciences announces key appointments and closing of $51m Series B financing
Back To News
Vascular Therapies announces clinical results from its Phase 3 randomized multicenter clinical trial
May 11, 2021

Vascular Therapies announces clinical results from its Phase 3 randomized multicenter clinical trial

Vascular Therapies, a privately held biotechnology company is developing Sirogen, a proprietary sirolimus formulation for intraoperative local drug delivery to reduce surgical stenosis in blood vessels. Today the company announced clinical results from its Phase 3 clinical trial in which Sirogen showed encouraging AV fistula outcomes in elderly end-stage renal disease patients.